Published in Drug Week, June 25th, 2004
Based on this designation, the FDA has established a target date of January 15, 2005, for completion of review of the Onco TCS NDA.
The NDA is seeking marketing approval for Onco TCS as a single-agent treatment for patients with relapsed aggressive non-Hodgkin lymphoma (NHL) previously treated with at least two combination chemotherapy regimens.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.